Compare EYE & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EYE | GENB |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2017 | N/A |
| Metric | EYE | GENB |
|---|---|---|
| Price | $17.61 | $16.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $31.22 | $23.20 |
| AVG Volume (30 Days) | ★ 2.4M | 890.1K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,987,488,000.00 | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $6.58 | $16.58 |
| P/E Ratio | $44.16 | ★ N/A |
| Revenue Growth | ★ 9.00 | N/A |
| 52 Week Low | $14.75 | $11.00 |
| 52 Week High | $30.02 | $16.75 |
| Indicator | EYE | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 63.07 |
| Support Level | $14.84 | $11.73 |
| Resistance Level | $29.56 | $16.75 |
| Average True Range (ATR) | 1.00 | 1.17 |
| MACD | 0.26 | 0.34 |
| Stochastic Oscillator | 60.94 | 87.34 |
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.